Australian researchers have developed a novel synthetic lipopeptide conjugate vaccine delivered via inhalation to the pulmonary mucosa that increased immunogenicity and efficacy against tuberculosis (TB) in a pre-clinical model. As reported in the Journal of Medicinal Chemistry, the experimental vaccine stimulated a strong Th17-like CD4+ T-lymphocyte response in a mouse model. Importantly, it was also ...
Already a member?
Enter your email to keep reading.